PPD confirms Takeda’s NDA submission of diabetes drugs to FDA
Under PPD’s agreement with Takeda, the submission of the new drug application for alogliptin and Actos does not trigger a milestone payment to PPD. If the new drug
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.